Abnormal Proliferation
Targeted Cancer Therapies
mTOR Signaling and Cancer Progression
The Retinoblastoma Gene
Rous Sarcoma Virus (RSV) and Cancer
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Masamitsu Mikami1, Tatsuya Masuda2, Takuya Kanatani2
1Department of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto 606-8303, Japan.
Targeting the RUNX1-survivin axis shows promise for treating aggressive pediatric malignant rhabdoid tumors (MRT). Inhibiting RUNX1 reduces survivin, suppressing MRT cell proliferation in preclinical models.
09:21Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
Published on: September 13, 2019
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: